Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 1/20 | 1.00 |
| ▸ | PTGS2 | P35354 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | TSHR | P16473 | 1/20 | 1.00 |
| ▸ | PSEN1 | P49768 | 4/20 | 0.56 |
| ▸ | ALOX5 | P09917 | 3/20 | 0.49 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.49 |
| ▸ | BCHE | P06276 | 5/20 | 0.47 |
| ▸ | ACHE | P22303 | 5/20 | 0.47 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | GSTP1 | P09211 | 1/20 | 0.45 |
| ▸ | TTPA | P49638 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | USP2 | O75604 | 1/20 | 0.45 |
| ▸ | THRB | P10828 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trolox SCHEMBL1927837 | 1.00 | PTGS1 (1.00) | PTGS1PTGS2CYP1A2CYP3A4TSHR | |
| Trolox SCHEMBL3226 | 1.00 | PTGS1 (1.00) | PTGS1PTGS2CYP1A2CYP3A4TSHR | |
| Trolox SCHEMBL29375939 | 1.00 | PTGS1 (1.00) | PTGS1PTGS2CYP1A2CYP3A4TSHR | |
| Trolox SCHEMBL29653919 | 1.00 | PTGS1 (1.00) | PTGS1PTGS2CYP1A2CYP3A4TSHR | |
| Trolox SCHEMBL4647438 | 1.00 | PTGS1 (1.00) | PTGS1PTGS2CYP1A2CYP3A4TSHR | |
| Trolox SCHEMBL1651402 | 1.00 | PTGS1 (1.00) | PTGS1PTGS2CYP1A2CYP3A4TSHR | |
| Trolox SCHEMBL7895023 | 0.96 | PTGS1 (0.91) | PTGS1PTGS2CYP1A2CYP3A4TSHR | |
| Trolox SCHEMBL17713594 | 0.94 | PTGS1 (0.89) | PTGS1PTGS2CYP1A2CYP3A4TSHR | |
| Trolox SCHEMBL8523345 | 0.93 | PTGS1 (0.86) | PTGS1PTGS2CYP1A2CYP3A4TSHR | |
| Trolox SCHEMBL20746198 | 0.92 | PTGS1 (0.84) | PTGS1PTGS2CYP1A2CYP3A4TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 209 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12509434-B2 | Optically resolved Trolox intermediate and method for producing same | PTC THERAPEUTICS, INC. (US) | 2025-12-30 | — | — | US | claimed |
| EP-4661890-A1 | PTP1B/TC-PTP DUAL INHIBITORS AND PROTEIN DEGRADERS | Purdue Research Foundation (US) | 2025-12-17 | — | — | EP | claimed |
| CN-115066420-B | Optically resolved Trolox intermediates and methods of making the same | PTC医疗公司 | 2024-12-10 | — | — | CN | claimed |
| WO-2024167565-A1 | PTP1B/TC-PTP DUAL INHIBITORS AND PROTEIN DEGRADERS | PURDUE RESEARCH FOUNDATION (US) | 2024-08-15 | — | — | WO | claimed |
| US-20230029044-A1 | OPTICALLY RESOLVED TROLOX INTERMEDIATE AND METHOD FOR PRODUCING SAME | PTC THERAPEUTICS, INC. | 2023-01-26 | — | — | US | claimed |
| EP-4108658-A1 | OPTICALLY RESOLVED TROLOX INTERMEDIATE AND METHOD FOR PRODUCING SAME | Sumitomo Pharma Co., Ltd. (JP) | 2022-12-28 | — | — | EP | claimed |
| CN-115066420-A | Optically resolved Trolox intermediates and process for producing the same | 住友制药株式会社 | 2022-09-16 | — | — | CN | claimed |
| US-10072043-B2 | Inhibitors of protein tyrosine phosphatases | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2018-09-11 | — | — | US | claimed |
| US-20180170892-A1 | COMPOUND FOR THE PROPHYLAXIS OR TREATMENT OF ORGAN DAGAMAGE | SULFATEQ B.V. (NL) | 2018-06-21 | — | — | US | claimed |
| EP-3297625-A1 | COMPOUND FOR THE PROPHYLAXIS OR TREATMENT OF ORGAN DAMAGE | Sulfateq B.V. (NL) | 2018-03-28 | — | — | EP | claimed |
| EP-1504002-B1 | METHOD FOR THE PRODUCTION OF OPTICALLY ACTIVE BETA-AMINOKETONES AND OPTICALLY ACTIVE 1,3-AMINOALCOHOLS | SANOFI AVENTIS DEUTSCHLAND (DE) | 2012-12-19 | — | — | EP | claimed |
| US-20120088720-A1 | INHIBITORS OF PROTEIN TYROSINE PHOSPHATASES | INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATI (US) | 2012-04-12 | — | — | US | claimed |
| WO-2010118241-A2 | INHIBITORS OF PROTEIN TYROSINE PHOSPHATASES | INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION (US) | 2010-10-14 | — | — | WO | claimed |
| US-7161008-B2 | Optically active β-aminoketones, optically active 1,3-amino alcohols and processes for preparing them | Sanofi - Aventis Deutschland GmbH (DE) | 2007-01-09 | — | — | US | claimed |
| EP-1504002-A1 | OPTICALLY ACTIVE &bgr;-AMINOKETONES, OPTICALLY ACTIVE 1,3-AMINOALCOHOLS AND METHOD FOR THE PRODUCTION THEREOF | Aventis Pharma Deutschland GmbH (DE) | 2005-02-09 | — | — | EP | claimed |
| US-20040030145-A1 | Optically active B-aminoketones, optically active 1,3-amino alcohols and processes for preparing them | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-02-12 | — | — | US | claimed |
| WO-2003093259-A1 | OPTICALLY ACTIVE β-AMINOKETONES, OPTICALLY ACTIVE 1,3-AMINOALCOHOLS AND METHOD FOR THE PRODUCTION THEREOF | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2003-11-13 | — | — | WO | claimed |
| US-20030064972-A1 | Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis | MPM ASSET MANAGEMENT INVESTORS 2002 BVIII LLC | 2003-04-03 | — | — | US | claimed |
| EP-1276730-A2 | THIAZOLIDINEDIONE ANALOGUES AND THEIR USE FOR THE TREATMENT OF DIABETES | ARYx Therapeutics (US) | 2003-01-22 | — | — | EP | claimed |
| WO-2001081328-A2 | THIAZOLIDINEDIONE ANALOGUES AND THEIR USE FOR THE TREATMENT OF DIABETES | ARYX THERAPEUTICS (US) | 2001-11-01 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12509434-B2 | Optically resolved Trolox intermediate and method for producing same | CYP11B2, ACAD9, TXNRD2 | PTGS1 2003/4885PTGS2 1078/4885CYP1A2 395/4885 |
| US-10072043-B2 | Inhibitors of protein tyrosine phosphatases | PTPRCAP, PTPRF, PTPRS | PTGS1 3346/4885PTGS2 3853/4885CYP1A2 4223/4885 |
| US-20040030145-A1 | Optically active B-aminoketones, optically active 1,3-amino alcohols and processes for preparing them | ORMDL3, OR10J3, BCAT2 | PTGS1 3472/4885PTGS2 3604/4885CYP1A2 429/4885 |
| US-20030064972-A1 | Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis | LIPA, LIPC, CETP | PTGS1 1370/4885PTGS2 814/4885CYP1A2 254/4885 |
| US-20230029044-A1 | OPTICALLY RESOLVED TROLOX INTERMEDIATE AND METHOD FOR PRODUCING SAME | ALDH1A2, TTPA, AOX1 | PTGS1 583/4885PTGS2 217/4885CYP1A2 74/4885 |
| US-20120088720-A1 | INHIBITORS OF PROTEIN TYROSINE PHOSPHATASES | PTPRCAP, PTPRF, PTPRS | PTGS1 3346/4885PTGS2 3853/4885CYP1A2 4223/4885 |
| US-20180170892-A1 | COMPOUND FOR THE PROPHYLAXIS OR TREATMENT OF ORGAN DAGAMAGE | LIPG, GLS, TXN2 | PTGS1 75/4885PTGS2 109/4885CYP1A2 1406/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.